The EU: what's best for UK cancer research and patients?
Lancet Oncol
.
2016 May;17(5):556-7.
doi: 10.1016/S1470-2045(16)30063-8.
Epub 2016 Apr 27.
Authors
Peter Selby
1
,
Mark Lawler
2
,
Ian Banks
3
,
Patrick Johnston
4
,
Paul Nurse
5
Affiliations
1
Cancer Medicine, University of Leeds, Leeds, UK; European Cancer Concord, Leeds, UK. Electronic address: p.j.selby@leeds.ac.uk.
2
School of Medicine, Dentistry and Biomedical Sciences, Belfast, Northern Ireland, UK; European Cancer Concord, Leeds, UK.
3
European Cancer Concord, Leeds, UK.
4
Queens University Belfast, Belfast, Northern Ireland, UK; European Cancer Concord, Leeds, UK.
5
European Cancer Concord, Leeds, UK; Francis Crick Institute, London, UK.
PMID:
27301027
DOI:
10.1016/S1470-2045(16)30063-8
No abstract available
MeSH terms
Biomedical Research* / organization & administration
European Union
Humans
Neoplasms*
United Kingdom
Grants and funding
RP-PG-0707-10101/DH_/Department of Health/United Kingdom